unpreced
global
spread
highli
pathogen
avian
influenza
virus
within
past
ten
year
extrem
lethal
poultri
human
underscor
potenti
caus
influenza
pandem
combat
threat
impend
influenza
pandem
requir
combin
pharmaceut
nonpharmaceut
intervent
strategi
emerg
pandem
emphasis
unpredict
natur
pandem
influenza
undoubtedli
vaccin
offer
viabl
mean
combat
pandem
threat
current
eggbas
influenza
vaccin
manufactur
strategi
unlik
abl
cater
huge
rapid
global
demand
anticip
scarciti
embryon
egg
avian
influenza
pandem
factor
associ
vaccin
product
process
therefor
altern
eggindepend
vaccin
manufactur
strategi
evalu
supplement
tradit
eggderiv
influenza
vaccin
manufactur
furthermor
evalu
dosespar
strategi
offer
protect
reduc
antigen
dose
critic
pandem
influenza
prepared
develop
new
antivir
therapeut
nonpharmaceut
intervent
strategi
supplement
pandem
prepared
review
highlight
current
statu
eggdepend
eggindepend
strategi
avian
influenza
pandem
nih
public
access
three
major
influenza
pandem
ref
furthermor
saw
develop
centuri
spanish
flu
asian
flu
mexican
flu
pandem
fig
pandem
hong
kong
flu
collect
aris
novel
influenza
strain
emerg
account
million
death
worldwid
infect
spread
effici
immunolog
naiv
human
popul
chang
influenza
viral
genom
occur
one
two
way
accumul
genet
mutat
antigen
drift
due
host
select
pressur
andor
faulti
viral
rna
polymeras
activ
exchang
one
fragment
segment
genom
genet
reassort
influenza
virus
coinfect
cell
lead
express
novel
surfac
antigen
antigen
shift
genet
novelti
asian
hong
kong
pandem
influenza
virusesclassifi
respect
accord
subtyp
surfac
glycoprotein
haemagglutinin
h
neuraminidas
n
express
result
genet
reassort
human
avian
influenza
virus
probabl
due
coinfect
pig
ref
fig
recent
evid
suggest
genet
novelti
spanish
pandem
influenza
viru
possibl
due
direct
transmiss
avian
influenza
viru
human
although
absolut
origin
viru
remain
unknown
ref
anoth
studi
indic
probabl
three
pandem
influenza
strain
centuri
may
gener
seri
multipl
reassort
event
ref
recent
mexican
flu
pandem
also
caus
reassort
avian
pig
human
virus
produc
novel
viru
abl
spread
rapidli
worldwid
limit
pathogen
ref
prior
mexican
flu
pandem
outbreak
past
ten
year
human
influenza
caus
highli
pathogen
avian
influenza
hpai
viru
caus
seriou
concern
high
lethal
fig
although
viru
current
show
effici
humanhuman
transmiss
consid
prepandem
outbreak
influenza
hong
kong
result
direct
transmiss
entir
avian
influenza
viru
human
ref
result
document
case
respiratori
diseas
includ
six
death
ref
amino
acid
chang
polymeras
protein
specif
identifi
viru
also
seen
virus
ref
virus
isol
two
human
case
hong
kong
one
fatal
ref
sinc
human
infect
virus
spread
sever
countri
asia
europ
africa
ref
account
case
case
fatal
fig
viru
transmiss
within
migratori
aquat
bird
backandforth
transmiss
poultri
popul
spread
human
due
close
contact
diseas
bird
well
document
furthermor
viru
caus
signific
infect
dog
tiger
cat
stone
marten
perhap
mammal
indic
expand
host
rang
ref
addit
influenza
human
caus
respiratori
infect
human
avian
influenza
subtyp
document
hong
kong
southern
china
netherland
ref
event
highlight
potenti
avian
influenza
virus
caus
pandem
emerg
avianhuman
reassort
capabl
human
transmiss
ref
renew
interest
develop
vaccin
strategi
capabl
induc
broad
crossreact
immun
novel
influenza
viru
variant
particular
highli
pathogen
emerg
mexican
flu
earli
declar
pandem
world
health
organ
earli
june
provid
enough
time
largescal
strainmatch
eggbas
vaccin
prepar
onset
regular
influenza
season
northern
hemispher
howev
million
target
million
dose
vaccin
avail
octob
usa
ref
thu
ongo
pandem
serv
remind
evalu
modifi
pandem
prepared
plan
estim
econom
impact
pandem
highli
pathogen
viru
would
us
billion
usa
alon
estim
death
hospitalis
million
outpati
visit
million
addit
ill
ref
us
food
drug
administr
fda
approv
pandem
influenza
vaccin
offer
limit
protect
differ
strain
antigen
distinct
strain
categoris
variou
clade
subclad
ref
offer
new
challang
vaccin
design
need
new
vaccin
technolog
provid
longlast
broad
immun
highli
pathogen
influenza
viru
although
vaccin
first
choic
pharmaceut
intervent
season
pandem
influenza
use
antivir
drug
also
crucial
intervent
strategi
pandem
prepared
antivir
use
either
treatment
prophylaxi
fda
licens
four
antivir
drug
influenza
therapi
ref
drug
fall
broadli
two
categori
blocker
influenza
matrix
protein
ion
channel
adamantan
deriv
amantadin
rimantadin
neuraminidas
inhibitor
zanamivir
oseltamivir
antivir
offer
import
intervent
strategi
pandem
prepared
stockpil
longer
shelf
life
vaccin
requir
refriger
howev
increas
report
drug
resist
hpai
virus
ref
season
influenza
virus
ref
major
virus
isol
vietnam
thailand
resist
adamantan
ref
recent
resist
viru
oseltamivir
also
report
ref
recent
resist
oseltamivir
two
differ
cluster
immunocompromis
hospit
patient
report
persontoperson
transmiss
suspect
cluster
ref
situat
alarm
oseltamivir
drug
choic
stockpil
part
pandem
prepared
mani
countri
ref
scenario
acceler
develop
evalu
new
antivir
agent
direct
toward
establish
target
neuraminidas
toward
unexplor
viral
target
well
hostcel
molecul
latter
includ
surfac
viral
receptor
eg
remov
host
cellsurfac
sialic
acid
primari
receptor
bind
entri
influenza
virus
host
cell
ref
compon
innat
immun
system
tolllik
receptor
ref
issu
guidanc
nonpharmaceut
public
health
intervent
nation
commun
level
reduc
exposur
suscept
individu
pandem
influenza
virus
ref
guidelin
base
evalu
histor
current
observ
supplement
mathemat
model
commun
mitig
strategi
intend
delay
reduc
impact
sever
pandem
limit
spread
diseas
vaccin
avail
mitig
strategi
involv
social
distanc
measur
close
school
childcar
centr
avoid
crowd
isol
patient
quarantin
contact
person
protect
hygien
measur
wear
mask
public
place
frequent
hand
wash
cover
one
mouth
nose
cough
sneez
avoid
spit
ref
measur
alreadi
appli
respons
influenza
pandem
although
correl
protect
influenza
infect
defin
hi
titr
assay
inhibit
haemagglutinininduc
erythrocyt
clump
accept
standard
measur
function
influenzaspecif
serum
antibodi
haemagglutinin
follow
vaccin
per
european
committe
proprietari
medicin
product
chmp
ref
us
food
drug
administr
fda
guidelin
ref
endpoint
hi
pandem
influenza
vaccin
licensur
percentag
particip
reciproc
titr
defin
seroposit
seroprotect
threshold
season
influenza
proport
particip
seroconvert
percentag
peopl
vaccin
reciproc
titr
vaccin
titr
vaccin
show
signific
increas
antibodi
titr
percentag
peopl
vaccin
reciproc
titr
vaccin
least
fourfold
increas
titr
vaccin
howev
sever
concern
regard
use
endpoint
hi
titr
evalu
protect
efficaci
pandem
influenza
question
remain
whether
titr
use
univers
influenza
strain
reflect
protect
naiv
popul
still
indic
protect
chang
assay
procedur
enhanc
sensit
new
viru
strain
ref
ideal
prepandem
vaccin
highli
immunogen
elicit
broad
immun
respons
innat
humor
cellular
low
antigen
dose
deliv
singl
shot
offer
protect
across
antigen
distinct
clade
efficaci
individu
differ
age
group
health
statu
method
vaccin
administr
suitabl
mass
vaccin
amen
rapid
costeffect
flexibl
scalabl
manufactur
durabl
shelf
life
prefer
room
temperatur
therebi
preclud
need
refriger
ref
sever
strategi
current
evalu
search
ideal
pandem
influenza
vaccin
depict
figur
almost
imposs
predict
characterist
next
influenza
pandem
strain
prepandem
vaccin
abl
induc
degre
crossprotect
haemagglutininspecif
humor
respons
conservednucleoproteinspecif
cellular
immun
respons
would
like
provid
reason
protect
haemagglutininsubtyp
specif
vaccin
becom
avail
current
two
type
influenza
vaccin
approv
clinic
use
manufactur
embryon
chicken
egg
live
attenu
influenza
vaccin
laiv
inactiv
influenza
vaccin
whole
subvirion
ref
howev
context
pandem
eggderiv
vaccin
sever
limit
ref
follow
procur
certifi
egg
entir
process
vaccin
manufactur
take
approxim
five
six
month
determin
vaccin
strain
vaccin
releas
ref
moreov
difficulti
adapt
viru
strain
effici
replic
egg
retain
antigen
genet
fidel
often
encount
season
influenza
vaccin
product
potenti
suscept
chicken
hpai
virus
jeopardis
avail
egg
vaccin
product
event
pandem
strain
aris
hpai
viru
nonetheless
yield
apuerto
reassort
provid
seed
major
inactiv
influenza
vaccin
higher
egg
continu
cell
line
ref
recent
improv
product
yield
dosespar
led
enhanc
current
eggbas
vaccin
manufactur
capac
threefold
past
year
ref
coldadapt
live
attenu
vaccinesth
fdaapprov
laiv
season
influenza
gener
use
attenu
master
donor
vaccin
strain
aann
grow
high
titr
egg
eggadapt
optimum
growth
reduc
replic
coldadapt
ca
reassort
master
donor
viru
isol
predict
circul
specif
influenza
season
result
vaccin
express
six
gene
segment
deriv
attenu
master
donor
strain
impart
reduc
abil
system
replicationdiseas
remain
two
gene
segment
haemagglutinin
neuraminidas
deriv
circul
relev
pandem
epidem
strain
ref
laiv
note
advantag
inactiv
counterpart
mimic
natur
infect
induc
rapid
robust
mucos
system
immun
respons
ref
laiv
also
shown
efficaci
highrisk
popul
chronic
ill
subject
suffer
chronic
obstruct
pulmonari
diseas
copd
ref
efficaci
laiv
evalu
healthi
children
recurr
respiratori
tract
infect
asthma
ref
specif
comparatiav
studi
trival
laiv
vaccin
consist
three
influenza
virus
two
differ
influenza
type
strain
one
influenza
type
b
strain
inactiv
trival
influenza
vaccin
consist
recombin
influenza
strain
demonstr
compar
safeti
better
efficaci
laiv
infant
young
children
ref
report
indic
laiv
gener
also
confer
degre
crossprotect
ref
needleless
intranas
administr
laiv
make
approach
ideal
vaccin
children
preclud
need
train
personnel
vaccin
administr
thu
make
amen
rapid
mass
vaccin
pandem
situat
moreov
higher
amount
viru
per
egg
produc
trival
inactiv
influenza
vaccin
therebi
enhanc
vaccin
coverag
exist
manufactur
capac
offer
potenti
advantag
term
pandem
prepared
ref
despit
potenti
advantag
year
sever
concern
arisen
laiv
advers
reaction
vaccin
revers
wild
type
viru
shed
reduc
efficaci
led
limit
accept
laiv
tosh
unfortun
success
season
trival
laiv
replic
pandem
vaccin
candid
laiv
meet
requir
european
committe
proprietari
medicin
product
chmp
immunogen
adult
seroprotect
rate
must
exceed
seroconvers
rate
must
least
elderli
subject
respect
limit
box
clinic
trial
studi
subject
age
wholeviru
inactiv
vaccineshistor
wholeviru
inactiv
vaccin
gener
use
genet
reassort
similar
describ
laiv
haemagglutinin
neuraminidas
gene
deriv
relev
circul
strain
major
differ
intern
gene
highyield
master
donor
strain
apuerto
subsequ
reassort
viru
subject
standard
formalin
inactiv
ref
split
prepar
chemic
disrupt
influenza
viru
subunit
prepar
antigen
protein
purifi
chemic
solubilis
influenza
viru
inactiv
vaccin
prefer
wholeviru
inactiv
vaccin
reactogen
especi
children
ref
nonetheless
inactiv
eggderiv
wholeviru
vaccin
shown
immunogen
produc
better
respons
naiv
popul
singl
dose
subunit
counterpart
ref
furthermor
use
wholeviru
vaccin
may
also
avoid
antigen
loss
disrupt
process
inactiv
splitvirion
vaccin
ref
alumadjuv
inactiv
wholeviru
vaccin
well
toler
result
seroposit
proport
individu
achiev
hi
titr
day
twodos
regimen
mg
per
dose
ref
adult
elderli
subject
respect
homolog
viru
also
show
signific
crossreact
immun
respons
differ
clade
virus
age
group
interestingli
higher
titr
virusneutralis
antibodi
crossreact
antibodi
detect
elderli
surpris
elderli
subject
also
seroconvert
strain
compar
adult
suggest
probabl
import
regular
vaccin
season
influenza
vaccin
develop
crossreact
immun
pandem
virus
ref
vaccin
shown
safe
immunogen
first
clinic
trial
children
healthi
children
year
receiv
singl
dose
mg
vaccin
seroconvert
day
vaccin
ref
owe
inher
low
immunogen
haemagglutinin
human
novel
adjuv
formul
inactiv
wholeviru
vaccin
enhanc
immunogen
also
lead
dosespar
howev
potenti
safeti
concern
regard
use
adjuv
inactiv
influenza
vaccin
becam
appar
intranas
vaccin
formul
introduc
switzerland
strongli
associ
bell
palsi
ref
suggest
need
largescal
safeti
trial
licensur
commerci
releas
new
vaccin
formul
sequel
studi
third
dose
vaccin
administ
six
month
second
dose
result
protect
antibodi
titr
subject
initi
receiv
mg
dose
respect
neutralis
antibodi
level
remain
significantli
higher
even
five
month
third
dose
compar
observ
second
dose
ref
note
howev
increas
amount
antigen
number
dose
viabl
strategi
pandem
prepared
term
time
econom
therefor
dosespar
use
novel
adjuv
strategi
requir
ref
signific
reduct
seroconvers
six
month
adult
elderli
howev
group
receiv
third
booster
dose
mg
show
seroprotect
better
adult
elderli
group
respect
vaccin
formul
also
gener
crossneutralis
antibodi
clade
viru
suggest
use
prepandem
scenario
importantli
age
group
ref
concept
proactiv
prepandem
prime
may
induc
longlast
immun
memori
allow
singl
booster
vaccin
induc
protect
gain
momentum
potenti
strategi
pandem
prepared
ref
two
mg
booster
dose
inactiv
nibrgm
vaccin
administ
subject
previous
least
six
year
earlier
prime
two
dose
either
nonadjuv
aduck
vaccin
contain
mg
haemagglutinin
booster
dose
induc
significantli
better
vaccin
respons
subject
prime
vaccin
term
earli
induct
persist
crossreact
antibodi
respons
six
month
unprim
subject
prime
unadjuv
vaccin
seven
day
administr
booster
subject
exhibit
high
titr
neutralis
antibodi
toward
divers
virus
well
origin
prime
strain
suggest
prime
vaccin
may
result
dosespar
limit
amount
number
dose
requir
achiev
seroprotect
titr
distinct
strain
might
due
induct
immun
memori
b
cell
pool
probabl
expand
rapidli
effici
booster
immunis
ref
recent
find
highlight
import
novel
adjuv
formul
primeboost
strategi
influenza
pandem
prepared
cellderiv
wholeviru
inactiv
vaccinesa
part
pandem
prepared
us
depart
health
human
servic
offer
substanti
monetari
incent
vaccin
industri
develop
cellbas
influenza
vaccin
infrastructur
usa
ref
major
vaccin
manufactur
variou
stage
develop
cellderiv
vaccin
season
pandem
influenza
ref
cellderiv
season
influenza
vaccin
alreadi
market
europ
ref
cellderiv
vaccin
assum
much
signific
respect
pandem
prepared
sinc
product
expos
anticip
vulner
suppli
embryon
egg
prepandem
pandem
scenario
addit
cellbas
vaccin
manufactur
close
scalabl
bioreactor
reduc
risk
exogen
contamin
follow
identif
pandem
strain
shorter
lead
manufactur
time
one
three
month
compar
approxim
five
six
month
eggbas
approach
ref
cellbas
product
influenza
vaccin
minimis
select
viru
variant
reduc
immunogen
alter
antigen
might
sometim
result
adapt
viru
strain
egg
eggbas
vaccin
manufactur
process
ref
howev
limit
cellbas
vaccin
approach
lack
standardis
reagent
potenti
safeti
concern
regard
introduct
adventiti
agent
cellbas
vaccin
manufactur
process
ref
date
three
cell
line
african
green
monkey
kidney
vero
madindarbi
canin
kidney
mdck
human
approv
influenza
vaccin
product
influenza
vaccin
produc
use
cell
line
test
sever
preclin
trial
ref
howev
use
cellderiv
wholeviru
vaccin
intact
haemagglutinin
polybas
cleavag
site
repres
potenti
public
health
hazard
fig
baculovirusmedi
protein
express
extrem
effici
strong
polyhedrin
promot
express
protein
undergo
posttransl
modif
similar
occur
mammalian
cell
ref
sever
clinic
trial
demonstr
safeti
immunogen
baculovirusexpress
recombin
haemagglutinin
ref
two
mg
dose
purifi
recombin
haemagglutinin
clade
viru
ahong
gener
potenti
protect
neutralis
antibodi
titr
naiv
subject
ref
followup
studi
eight
year
later
subject
subject
induc
potenti
protect
titr
immunis
singl
mg
dose
eggderiv
inactiv
subvirion
clade
vaccin
compar
nonprim
subject
receiv
two
mg
dose
vaccin
ref
suggest
prepandem
prime
may
reduc
global
vaccin
burden
pandem
scenario
use
better
adjuv
conserv
intern
protein
recombin
haemagglutinin
vaccin
formul
may
broaden
vaccin
efficaci
dna
vaccinesdna
vaccin
technolog
enabl
easi
manipul
incorpor
singl
multipl
gene
interest
plasmid
fig
furthermor
molecul
modul
stimul
immun
respons
also
incorpor
plasmid
boost
vaccin
efficaci
dna
vaccin
capabl
induc
humor
cellular
immun
respons
either
predomin
helper
respons
depend
rout
dna
deliveri
specif
intramuscular
inject
versu
gene
gun
deliveri
skin
respect
ref
demonstr
protect
efficaci
mous
model
advectorbas
influenza
vaccin
shown
safe
immunogen
human
ref
intranas
administr
twodos
regimen
viru
particl
express
haemagglutinin
apuerto
result
fourfold
increas
hi
titr
subject
clinic
trial
ref
sever
preclin
studi
suggest
hadvector
immun
presenc
preexist
hadspecif
neutralis
antibodi
might
inhibit
gener
immun
respons
transgen
product
ref
clinic
trial
specif
demonstr
increas
vaccin
dose
hadbas
hiv
vaccin
overcam
hadvector
immun
ref
nonetheless
use
nonhuman
advectorbas
vaccin
either
alon
boost
compon
dnaprim
advectorboost
immunis
strategi
use
combin
dna
advector
antigen
deliveri
system
ref
among
sever
altern
approach
explor
circumv
limit
hadvector
immun
bovineorigin
ad
vector
bovin
ad
subtyp
bad
base
vaccin
shown
circumv
high
level
preexist
hadvector
immun
mous
model
ref
vaccin
complet
protect
mice
homolog
viru
challeng
ref
addit
primeboost
strategi
use
bad
vector
gener
better
immun
respons
compar
respons
gener
either
vector
alon
suggest
import
two
vector
system
improv
vaccineinduc
immun
respons
ref
vsv
vector
develop
potenti
therapeut
vaccin
vector
variou
diseas
ref
recombin
vsv
express
haemagglutinin
viru
induc
robust
neutralis
antibodi
titr
homolog
recent
antigen
distinct
virus
mice
ref
singl
dose
vaccin
offer
durabl
protect
seven
month
lethal
challeng
homolog
viru
ref
vsv
vector
express
haemagglutinin
hpai
fpvrostock
place
vsv
g
gene
protect
chicken
challeng
homolog
viru
viru
ref
low
seropreval
vsv
human
make
suitabl
vector
human
applic
preclin
studi
requir
prove
use
design
pandem
influenza
vaccin
poxviru
vector
accommod
larg
multipl
gene
insert
approxim
kb
size
ref
modifi
vaccinia
viru
ankara
mva
recombin
express
influenza
viru
antigen
evalu
sever
preclin
trial
ref
antibodi
therapi
influenza
gain
interest
recent
year
due
potenti
rapidli
deliv
univers
therapeut
prophylact
remedi
pandem
influenza
strainssubtyp
pandem
transfus
convalesc
human
blood
product
patient
recov
spanish
flu
may
associ
reduct
pandem
death
rate
ref
recent
human
monoclon
antibodi
mab
gener
blood
convalesc
patient
result
protect
homolog
viru
challeng
mous
model
ref
sever
techniqu
rapidli
gener
influenzaspecif
human
mab
describ
ref
mab
demonstr
broad
heterosubtyp
neutralis
activ
ref
use
similar
techniqu
panel
highaffin
broadspectrum
human
neutralis
antibodi
nab
haemagglutinin
identifi
neutralis
activ
avian
sever
human
influenza
subtyp
ref
nab
protect
mice
lethal
dose
hpai
given
challeng
suggest
prophylact
therapeut
efficaci
ref
studi
broad
neutralis
activ
mab
due
bind
highli
conserv
pocket
stem
domain
haemagglutinin
inhibit
haemagglutininmedi
virushost
membran
fusion
ref
passiv
antibodi
therapi
direct
conserv
haemagglutinin
epitop
hold
promis
pandem
prepared
due
therapeut
prophylact
valu
potenti
abil
provid
broad
protect
conserv
epitop
could
exploit
design
univers
influenza
vaccin
human
histori
fraught
deadli
epidem
pandem
influenza
result
million
death
worldwid
never
humankind
plan
comprehens
control
prevent
influenza
pandem
fig
current
case
fatal
rate
potenti
higher
associ
hpai
viru
result
renew
fear
massiv
loss
human
life
event
influenza
pandem
year
remark
advanc
medicin
combat
infecti
diseas
howev
tightli
interlink
modern
global
commun
face
new
challeng
form
sever
acut
respiratori
syndrom
sar
outbreak
novel
influenza
pandem
worldwid
viru
spread
occur
remark
rapid
rate
rel
short
time
period
contrast
understand
influenza
transmiss
previou
influenza
pandem
combat
influenza
pandem
requir
concert
global
effort
part
intern
agenc
healthcar
industri
govern
individu
ongo
pandem
offer
valuabl
inform
regard
diseas
outbreak
spread
effect
contain
strategi
outlin
pandem
prepared
plan
variou
countri
develop
influenza
vaccin
provid
broad
durabl
protect
low
antigen
dose
cornerston
pandem
prepared
plan
howev
prepandem
vaccin
strategi
good
abil
predict
pandem
viru
strain
ampli
demonstr
onset
current
pandem
midst
prepar
probabl
pandem
eggbas
influenza
vaccin
manufactur
strategi
backbon
season
influenza
vaccin
product
decad
might
longer
support
massiv
global
requir
pandem
vaccin
although
eggbas
vaccin
product
ongo
pandem
initi
soon
identif
pandem
strain
issu
low
viru
yield
result
delay
time
avail
enough
vaccin
dose
inabl
eggbas
strategi
quickli
produc
massiv
dose
necessari
vaccin
time
manner
clearli
emphasis
need
explor
altern
eggindepend
vaccin
strategi
complement
exist
capac
also
ensur
rapid
scalabl
sever
technolog
altern
supplement
current
eggbas
approach
explor
tabl
cellderiv
seasonalpandem
vaccin
look
promis
clinic
trial
licens
europ
like
licens
near
futur
elsewher
vlpbase
influenza
vaccin
rapidli
catch
result
safeti
immunogen
vaccin
base
viral
vector
dna
vaccin
technolog
also
gain
momentum
recent
year
thu
ad
grow
list
eggindepend
strategi
pandem
influenza
vaccin
howev
lack
offici
calibr
reagent
assay
evolv
eggindepend
technolog
major
impedi
regulatori
approv
simplifi
regulatori
process
fasttrack
approv
vaccin
prepandem
pandem
scenario
regulatori
agenc
improv
effect
pandem
prepared
plan
antivir
offer
therapeut
intervent
strategi
first
phase
influenza
pandem
novel
antivir
molecul
reduc
risk
drugresist
need
identifi
evalu
sinc
current
avail
antivir
rapidli
lose
reliabl
recent
gener
mab
direct
toward
conserv
haemagglutinin
epitop
could
potenti
provid
rapid
broad
protect
requir
clinic
evalu
addit
vaccin
antivir
howev
comprehens
pandem
prepared
plan
also
includ
nonpharmaceut
intervent
strategi
limit
spread
pandem
viru
control
spread
viru
assum
even
greater
signific
modern
global
interlink
environ
develop
divers
vaccin
antivir
strategi
offer
flexibl
plan
plausibl
intervent
strategi
peopl
vari
geograph
econom
set
ongo
pandem
may
shift
focu
threat
influenza
pandem
still
remain
signific
inform
regard
viru
serotyp
involv
pandem
reassort
featur
estim
number
human
death
includ
emerg
highli
pathogen
avian
influenza
hpai
virus
also
present
influenza
viru
vaccin
candid
grown
egg
certifi
cell
line
chemic
inactiv
gener
inactiv
influenza
vaccin
live
attenu
influenza
vaccin
gener
reassort
eggadapt
coldadapt
attenu
master
donor
vaccin
strain
grow
high
titr
egg
optimum
growth
reduc
replic
circul
epidem
pandem
strain
result
vaccin
viru
express
six
gene
segment
deriv
attenu
master
donor
strain
remain
two
gene
segment
haemagglutinin
neuraminidas
deriv
circul
relev
epidem
pandem
strain
reassort
virus
propag
egg
certifi
cell
line
bulk
prepar
purif
b
recombin
baculoviru
express
haemagglutinin
ha
protein
insect
cell
grown
bulk
influenza
vaccin
base
purifi
immunogen
c
viruslik
particl
vaccin
highli
organis
particl
deriv
self
assembl
viral
structur
protein
exampl
ha
neuraminidas
na
matrix
express
baculovirusyeast
vector
system
insect
cell
dna
vaccin
plasmid
design
robust
express
vacine
driven
strong
viral
promot
also
includ
polyadenyl
signal
gene
encod
immunestimulatori
molecul
eg
cytokin
interleukin
il
may
also
includ
separ
plasmid
e
viralvector
vaccin
deriv
rang
virus
wherein
antigen
influenza
viru
protein
isar
express
strong
promot
viral
vector
deriv
adenoviru
accommod
multipl
gene
encod
ha
differ
influenza
strain
subtyp
influenza
antigen
protein
conserv
nucleoprotein
np
protein
serv
live
vaccin
platform
without
associ
risk
infect
pharmaceut
approach
includ
antivir
drug
passiv
antibodi
therapi
vaccin
deriv
convent
eggbas
technolog
eggindepend
technolog
fig
develop
use
novel
adjuv
key
dosespar
enhanc
vaccin
coverag
simpl
nonpharmaceut
measur
individu
commun
intern
level
go
long
way
curtail
rapid
spread
pandem
influenza
